Mometasone eluting resorbable scaffold - Lyra Therapeutics
Alternative Names: LYR-210; LYR-220; Mometasone furoate sinus drug depotLatest Information Update: 11 Jun 2025
At a glance
- Originator 480 Biomedical
- Developer Lyra Therapeutics
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated hydrocarbons; Furans; Glucocorticoids; Phenanthrenes; Pregnadienediols; Skin disorder therapies; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rhinosinusitis
Most Recent Events
- 02 Jun 2025 Efficacy and adverse events data from phase III ENLIGHTEN II trial in Rhinosinusitis released by Lyra Therapeutics
- 02 Jun 2025 Pooled efficacy data from phase III ENLIGHTEN I and ENLIGHTEN II trial in Rhinosinusitis released by Lyra Therapeutics
- 02 Apr 2025 Lyra Therapeutics completes the phase III ENLIGHTEN 2 trial for Rhinosinusitis (In adults, In the elderly) in Belgium, Bulgaria, Germany, Hungary, Poland, USA (Intranasal) (NCT05295459)